Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26882190 | 1.00 | PIK3CA (0.39) | PIK3CAPIK3CBCDK2AKT1AKT2 | |
| SCHEMBL27134169 | 0.87 | PIK3CA (0.38) | PIK3CAPIK3CBCDK2AKT1AKT2 | |
| SCHEMBL27008509 | 0.87 | PIK3CA (0.38) | PIK3CAPIK3CBCDK2AKT1AKT2 | |
| SCHEMBL26662323 | 0.87 | CYP1A1 (0.41) | PIK3CAPIK3CBCDK2AKT1AKT2 | |
| SCHEMBL26662326 | 0.87 | CYP1A1 (0.41) | PIK3CAPIK3CBCDK2AKT1AKT2 | |
| SCHEMBL30584381 | 0.87 | CYP1A1 (0.41) | PIK3CAPIK3CBCDK2AKT1AKT2 | |
| SCHEMBL27129359 | 0.86 | PIK3CB (0.33) | PIK3CAPIK3CBCDK2AKT1AKT2 | |
| SCHEMBL26884634 | 0.86 | PIK3CB (0.33) | PIK3CAPIK3CBCDK2AKT1AKT2 | |
| SCHEMBL27135536 | 0.84 | CYP1A1 (0.42) | PIK3CACDK2AKT1AKT2AKT3 | |
| SCHEMBL26881276 | 0.84 | CYP1A1 (0.42) | PIK3CACDK2AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PIK3CB 16/4885CDK2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.